Evidence map›Paper›PMID 37109629›Full record

ArticleMedicina (Kaunas, Lithuania)2023

The Philadelphia Chromosome, from Negative to Positive: A Case Report of Relapsed Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.

Elena-Cristina Marinescu, Horia Bumbea, Iuliana Iordan, Ion Dumitru, Dan Soare, Cristina Ciufu, Mihaela Gaman

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elena-Cristina MarinescuDepartment of Methodology and Scientific Research, "Carol Davila" University of Medicine and Pharmacy, Eroilor Sanitari Boulevard, No. 8, 050474 Bucharest, Romania.ORCID 0000-0001-7544-4974
Horia BumbeaDepartment of Methodology and Scientific Research, "Carol Davila" University of Medicine and Pharmacy, Eroilor Sanitari Boulevard, No. 8, 050474 Bucharest, Romania.
Iuliana IordanDepartment of Methodology and Scientific Research, "Carol Davila" University of Medicine and Pharmacy, Eroilor Sanitari Boulevard, No. 8, 050474 Bucharest, Romania.
Ion DumitruDepartment of Hematology, Emergency University Hospital of Bucharest, Splaiul Independentei, No. 169, 050098 Bucharest, Romania.
Dan SoareDepartment of Methodology and Scientific Research, "Carol Davila" University of Medicine and Pharmacy, Eroilor Sanitari Boulevard, No. 8, 050474 Bucharest, Romania.
Cristina CiufuDepartment of Methodology and Scientific Research, "Carol Davila" University of Medicine and Pharmacy, Eroilor Sanitari Boulevard, No. 8, 050474 Bucharest, Romania.
Mihaela GamanDepartment of Hematology, Emergency University Hospital of Bucharest, Splaiul Independentei, No. 169, 050098 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROClinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsed acute lymphoblastic leukemia (ALL) represents a continuous challenge for the clinician. Despite recent advances in treatment, the risk of relapse remains significant. The clinical, biological, cytogenetic, and molecular characteristics may be different at the time of relapse. Current comprehensive genome sequencing studies suggest that most relapsed patients, especially those with late relapses, acquire new genetic abnormalities, usually within a minor clone that emerges after ALL diagnosis. We report the case of a 23-year-old young woman diagnosed with Philadelphia chromosome-negative B cell acute lymphoblastic leukemia. The patient underwent allogeneic stem cell transplantation (allo-HSCT) after complete remission. Despite having favorable prognostic factors at diagnosis, the disease relapsed early after allo-HSCT. The cytogenetic and molecular exams at relapse were positive for the Philadelphia chromosome, respectively for the Bcr-Abl transcript. What exactly led to the recurrence of this disease in a more aggressive cytogenetic and molecular form, although there were no predictive elements at diagnosis?

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultChronic DiseaseFemaleHumansPhiladelphia ChromosomeRecurrenceRemission InductionYoung Adultacute lymphoblastic leukemiaallogeneic stem cell transplantationPhiladelphia chromosomerelapse

Identifiers

PMID37109629
PMCPMC10142475
OpenAlexW4361217678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.